Skip to main content
3-D Matrix,Ltd. logo

3-D Matrix,Ltd. - Investor Relations & Filings

Listed IPO Oct 2011
Ticker · 7777 ISIN · JP3410730000 T Manufacturing
Open in API
Filings indexed 140 across all filing types
Latest filing 2026-07-22 Share Issue/Capital Cha…
Country JP Japan
Listing T 7777 · 1 venue

Key figures FY2026

Period ended 2026-04-30 · JPY
Headline annual figures for 3-D Matrix,Ltd., fiscal year 2026, reported in JPY, with the source filing for each figure.
Total Revenues JPY 10.89M per the Earnings Release filed 2026-06-11
Net Income JPY 4.16M per the Earnings Release filed 2026-06-11
Total Assets JPY 9.80M per the Earnings Release filed 2026-06-11
Total Equity JPY 6.80M per the Earnings Release filed 2026-06-11
Cash from Ops JPY 396.85k per the Earnings Release filed 2026-06-11

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About 3-D Matrix,Ltd.

https://3dmatrix.com/

3-D Matrix, Ltd. is a global medical technology company specializing in the development and commercialization of products based on a proprietary self-assembling peptide technology. Originating from research at the Massachusetts Institute of Technology (MIT), this platform creates biocompatible hydrogels used primarily as hemostatic agents to control oozing bleeding during surgical and endoscopic procedures. The company's solutions are applied across various medical specialties, including gastroenterology, cardiac surgery, otolaryngology (ENT), and urology. 3-D Matrix is also advancing its peptide platform to develop new applications in wound healing, regenerative medicine, and drug delivery systems, aiming to provide clinically proven solutions that improve patient outcomes.

Recent filings

Filing Released Lang Actions
ストック・オプション（新株予約権）の発行内容確定に関するお知らせ
Share Issue/Capital Change Classification · 95% confidence The document is titled 'ストック・オプション（新株予約権）の発行内容確定に関するお知らせ' (Notice regarding the determination of issuance details for stock options/share acquisition rights). It outlines the finalization of the number of share acquisition rights, the number of shares, the exercise price, and the allotment to directors and employees. This corresponds to the issuance of new shares or capital changes through stock options, fitting the Share Issue/Capital Change (SHA) category.
2026-07-22 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a confirmation letter (確認書) submitted pursuant to Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act, confirming the appropriateness of the contents of the annual securities report (有価証券報告書). Per Rule 3 (Certification Rule), if a document is primarily an officer certification, attestation, or confirmation letter referencing a specific report type rather than the report itself, it must be classified under Regulatory Filings (RNS).
2026-07-22 Japanese
有価証券報告書－第22期(2025/05/01－2026/04/30)
Annual Report Classification · 100% confidence The document is titled '有価証券報告書' (Yukashoken Hokokusho, Annual Securities Report), which is the official Japanese statutory annual report filed pursuant to the Financial Instruments and Exchange Act. It covers a full fiscal year (2025/05/01 - 2026/04/30), contains comprehensive audited financial data, management discussion, and multi-year financial summaries. This matches the definition of a standard Annual Report (10-K equivalent). FY 2026
2026-07-22 Japanese
ストック・オプション（新株予約権）の発行に関するお知らせ
Regulatory Filings
2026-07-21 Japanese
2026年４月期通期決算及び中期経営計画説明会の質問について
Management Reports Classification · 95% confidence The document is a Q&A session between the company (3-D Matrix) and its investors regarding the fiscal year 2026 financial results and the medium-term management plan. It contains detailed management responses to specific questions about business strategy, financial performance, R&D, and corporate governance. While it discusses financial results, it is not an earnings release (ER) or a formal report (10-K/IR), but rather a supplementary document providing management's detailed explanation and outlook, which fits the definition of Management Reports (MDA).
2026-07-17 Japanese
ピュアリフトの承認整理に関するお知らせ
Regulatory Filings Classification · 95% confidence The document is an official announcement from 3-D Matrix Co., Ltd. regarding the 'approval arrangement' (withdrawal/cancellation) of their medical device 'PureLift' with the Ministry of Health, Labour and Welfare. It explains the reasons for the decision (supply chain issues, manufacturing costs) and the future strategic focus on the US market. It does not contain financial statements, audit reports, or proxy materials. As it is a regulatory announcement regarding a specific product's regulatory status and business operations, it falls under the 'Regulatory Filings' category as a general corporate announcement.
2026-06-26 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.